The new cobas ® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems.
Dec 17 (Reuters) - The White House is set to announce drug pricing deals with pharmaceutical giants Novartis (NOVN.S), opens new tab and Roche Holding (ROG.S), opens new tab as soon as Friday, ...
Dec 17 (Reuters) - The White House is set to announce drug pricing deals with pharma giants Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday, citing people ...
UK biotech Gyroscope Therapeutics is to merge with Orbit Biomedical of the US to create a specialist in gene therapies for eye diseases. The combined company – which will operate under the Gyroscope ...
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First ...
The past few decades have seen a dramatic shift in how human disorders can be treated. Growing knowledge of the molecular dynamics underlying physiological processes and technological advances are ...
This is a paper template used by CMU LeCAR Lab. It comes with a simple plot demo and a table demo. Usage: in overleaf, click import from GitHub and paste the URL of this repository. Or download the ...
INDIANAPOLIS, Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas ® 6800/8800 systems version 2.0 and software version 2.0.1, following U.S.
The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.
A comprehensive Typst template for creating official United States Air Force memorandums that comply with AFH 33-337 "The Tongue and Quill" formatting standards. Maintained by tonguetoquill.com. # ...
Abstract: Precise determination of HER2 subtype is essential for selecting appropriate targeted therapies in breast cancer. However, current HER2 assessment methods remain dependent on invasive tissue ...
Adaptive Capabilities,Cluster Centers,Conductive Polymers,Deep Learning,Electrode,Electromyography,Encoder-decoder,Fiber Counts,Fiber Width,Higher Maximum Values ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback